Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

Status unconfirmed · Phase 4

Conditions studied: Acute Stress Disorder

In brief

A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.

Key facts

Study ID

NCT04769297

Run by

Limbic Medical

People needed

30

Starts

2020-04-15

Expected to finish

2021-04-01

Last updated by the study team

2021-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Greater than 18 years of age
• Demonstrate capacity to consent to the study
• A Frontline Health Care Worker-defined as any EMS personnel (firefighter, EMT, flight nurse, etc.), or any hospital-based worker (particularly in the ED, ICU, or OR) such as an RN, MD/DO, or non-clinical support staff (EVS, etc.)
• Experiencing acute stress disorder as determined by clinically validated screening tools -

You may not qualify if…

• Currently on prescription medications for psychiatric issues
• Currently pregnant or breastfeeding or actively trying to get pregnant
• History of seizure disorder, liver disease, or psychosis/mania
• Uncontrolled Hypertension
• Physician discretion: any condition deemed inappropriate that will increase the risk -

Where it is running

• Limbic Medical — Toluca Lake, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.